Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of non-cash share-based compensation expense

Non-cash share-based compensation expense, consisting of expense for stock options, Restricted Share Units ("RSUs"), Performance Share Units ("PSU"), and Employee Share Purchase Plan ("ESPP"), was classified in the condensed

consolidated statements of operations and comprehensive loss as follows:

	Three months ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Research and development expenses	$	16,624	$	9,273	$	50,577	$	29,331
Selling, general and administrative expenses	23,643		16,313		71,518		44,981
Total non-cash share-based compensation expense	$	40,267	$	25,586	$	122,094	$	74,312
Less: Share-based compensation expense attributable to non-controlling interests	498		540		996		900
Share-based compensation expense attributable to Biohaven Pharmaceutical Holding Company Ltd.	$	39,769	$	25,046	$	121,098	$	73,412

Schedule of stock option activity

The following table is a summary of the Company's stock option activity for the six months ended June 30, 2022:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2021	7,089,727	$40.15
Granted	1,364,434	$126.36
Exercised	(76,161)	$57.92
Forfeited	(19,375)	$80.24
Outstanding as of June 30, 2022	8,358,625	$53.96	6.80	$	766,875
Options exercisable as of June 30, 2022	5,872,531	$39.75	6.12	$	622,280
Vested and expected to vest as of June 30, 2022	8,358,625	$53.93	6.80	$	766,875

Schedule of RSU activity

The following table is a summary of the RSU and PSU activity for the six months ended June 30, 2022:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested as of December 31, 2021	1,218,070	$78.98
Granted	1,184,787	$127.32
Forfeited	(30,530)	$99.69
Vested	(637,728)	$94.32
Unvested as of June 30, 2022	1,734,599	$106.00